INTRODUCTION: The purpose of this study was to evaluate hepatitis delta virus (HDV) testing patterns among US adults with chronic hepatitis B (CHB). METHODS:HDV testing was evaluated among CHB patients using Quest Diagnostics (2016-2020) and Veterans Affairs (2010-2020) data. RESULTS:Among 157,333 CHB patients (Quest), 6.7% received HDV testing, among which 2.2% were positive.HDV testing was higher in male patients, younger individuals, and patients with advanced liver disease. Among 12,002 CHB patients (Veterans Affairs), 19.7% received HDV testing, among which 3.1% were positive. HDV testing was higher in younger individuals and Asians.DISCUSSION:Low HDV testing was observed among 2 large US cohorts of adults with CHB.

EOT). Complete response (CR5HRS reversal) was defined as at least 1 serum creatinine (SCr) value of #1.5 mg/dL while on treatment. Partial response (PR) was defined as $30% improvement in SCr but not HRS reversal, and no response (NR) meant no change or worsening of SCr. EOT was defined as the last date/time of treatment plus 24 hours. Results: Baseline characteristics were compatible with decompensated liver disease and similar across treatment groups: in the Terli and Pbo groups, mean Model for End-Stage Liver Disease (MELD) (standard deviation [SD]) scores were 32.7 (6.6) and 33.1 (6.2), respectively. On average, hyponatremia was moderate. Mean (SD) serum Na levels in the safety population were almost identical: 133.1 (5.6) mmol/L and 133.3 (5.5) mmol/L, respectively. By EOT, serum Na levels increased significantly more in the Terli group vs the Pbo group, and in all clinical response categories defined by changes in SCr (Table ). The improvement in serum Na was numerically higher in pts who had a CR vs PR; however, they were similar in the CR and NR groups (Table ). Conclusion:In contrast to previous observations, by EOT, hyponatremia in pts with HRS-1 improved to a significantly higher level when treated with Terli vs Pbo in all response categories. The results suggest that the use of Terli is safe with respect to hyponatremia.

The epidemiology of latent tuberculosis and hepatitis B virus (HBV‐LTBI) co‐infection among U.S. populations is not well studied. We aim to evaluate LTBI testing patterns and LTBI prevalence among two large U.S. cohorts of adults with chronic HBV (CHB). Adults with CHB in the Chronic Hepatitis Cohort Study (CHeCS) and Veterans Affairs national cohort were included in the analyses. Prevalence of HBV‐LTBI co‐infection was defined as the number of HBV patients with LTBI divided by the number of HBV patients in a cohort. Multivariable logistic regression evaluated odds of HBV‐LTBI co‐infection among CHB patients who underwent TB testing. Among 6019 CHB patients in the CHeCS cohort (44% female, 47% Asian), 9.1% were tested for TB, among whom 7.7% had HBV‐LTBI co‐infection. Among HBV‐LTBI co‐infected patient, only 16.7% (n = 7) received LTBI treatment, among whom 28.6% (n = 2) developed DILI. Among 12,928 CHB patients in the VA cohort (94% male, 42% African American, 39% non‐Hispanic white), 14.7% were tested for TB, among whom 14.5% had HBV‐LTBI. Among HBV‐LTBI co‐infected patient, 18.6% (n = 51) received LTBI treatment, among whom 3.9% (n = 3) developed DILI. Presence of cirrhosis, race/ethnicity, and country of birth were observed to be associated with odds of HBV‐LTBI co‐infection among CHB patients who received TB testing. In summary, among two large distinct U.S. cohorts of adults with CHB, testing for LTBI was infrequent despite relatively high prevalence of HBV‐LTBI co‐infection. Moreover, low rates of LTBI treatment were observed among those with HBV‐LTBI co‐infection.

No abstract